re: Ann: Clover 2013FY Results - Investor Pre... Snip from the Tim Boreham from the Australian
"Microequities chief Carlos Gil expects the contamination impact to be "transitory" and confined to the current year. He says that, while pricing pressure is rising, the medical applications are potentially company-changing.
One is a clinical trial to improve the health of premature infants. The results of the 1250-patient effort are due by the end of next year.
Clover is a buy on recent share weakness."
To see the full story you can cut and paste the link into a google search (not the space bar) click on the story and it will come up without needing a subscription.
- See more at: http://www.theaustralian.com.au/business/opinion/milk-contamination-scare-only-transitory/story-e6frg9lo-1226722355624#sthash.T8vuEfrE.dpuf
- Forums
- ASX - By Stock
- Ann: Clover 2013FY Results - Investor Presentatio
re: Ann: Clover 2013FY Results - Investor Pre... Snip from the...
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CLV (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.0¢ |
Change
-0.005(1.01%) |
Mkt cap ! $60.11M |
Open | High | Low | Value | Volume |
49.0¢ | 49.5¢ | 49.0¢ | $8.983K | 18.23K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 32789 | 49.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.0¢ | 44797 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 7695 | 2.000 |
1 | 796 | 1.995 |
1 | 796 | 1.990 |
1 | 796 | 1.985 |
1 | 796 | 1.980 |
Price($) | Vol. | No. |
---|---|---|
2.030 | 7190 | 2 |
2.040 | 2620 | 3 |
2.050 | 16114 | 2 |
2.060 | 2764 | 2 |
2.070 | 3787 | 3 |
Last trade - 15.45pm 15/11/2024 (20 minute delay) ? |
Featured News
CLV (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online